American Academy of Neurology Annual Meeting 2020

Coverage of research and presentations accepted to the 2020 American Academy of Neurology Annual Meeting, which was canceled due to the COVID-19 pandemic. 
The chair of the Department of Neurosurgery at Banner-University Medical Center discusses the current state of the science being done in the realm of epilepsy surgery.
The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.
The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.
The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.
The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.
The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.
The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.
The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.
The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.
The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.
The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.
The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.
The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.
The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.
The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.